Back to Trials
NCT06999434PHASE1RecruitingAccepts Healthy Volunteers

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Yale University

Start Date

5/5/2025

Completion Date

5/5/2030

Summary

The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

Eligibility Criteria

Age Range: 18 years to 90 years

Inclusion: 1. Male and Female subjects must be ≥18 and \<90 years of age; 2. Able to understand and provide informed consent prior to study procedures 3. Must be in good health Exclusion: 1. Less than 18 years of age; 2. Pregnant or breastfeeding; 3. Any significant systemic illness or unstable medical condition; 4. Pre-existing medical conditions or claustrophobic reactions; 5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months); 6. History of a bleeding disorder or are currently taking anticoagulants.

Interventions

DRUG

[ 18F]3F4AP

DRUG

[18F]MK6240

DRUG

[11C]PIB

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Demyelinating DisordersMCIAlzheimer's Disease (AD)MS (Multiple Sclerosis)SCI - Spinal Cord InjurySpinal Radiculopathy

Locations

Yale University PET Center

New Haven, Connecticut 06510

United States